Anti-Obesity Drug Approved by FDA Panel

By Mayuri, Gaea News Network
Wednesday, December 8, 2010

WASHINGTON ( — After almost a decade an advisory panel of FDA has approved an anti-obese drug with a hope to minimize the obesity pandemic through out the world.

FDA has declined many drugs before after finding the heart attack or high blood pressure risk associated with it. But this new drug called Contrave is approved by the panel of FDA means that this drug outweighs its risks. Contrave which is made by Orexigen Therapeutics Inc. is voted 13 to 7 by the advisory panel.

As usual this drug is also associated with causing increased blood pressure and heart rate which is common problem with weight-loss drugs. FDA is expected to make the final decision on the month of January.

The FDA earlier this year acted on the panel’s recommendations and denied two new obesity drugs, Qnexa and Lorcaserin, over cancer and heart risks.

will not be displayed